Navigation Links
UCLA researchers show how world's smallest 'coffee ring' may help biosensors detect disease
Date:5/5/2010

kers on a checkerboard. The group repeated the experiments with smaller grid patterns until the coffee-ring phenomenon was no longer evident. For the 100-nanometer sized particles, this occurred at a droplet diameter of approximately 10 micrometers, or about 10 times smaller than the width of a human hair. At this point, the water evaporated before the particles had enough time to move to the perimeter.

"Knowing the minimum size of this so-called coffee ring will guide us in making the smallest biosensors possible," Wong said. "This means that we can pack thousands, even millions, of small micro-biosensors onto a lab-on-a-chip, allowing one to perform a large number of medical diagnostics on a single chip. This may also open the doors to potentially detecting multiple diseases in one sitting."

"There's another important advantage this whole process is very natural, it's just evaporation," Wong added. "We don't need to use additional devices, such as an electrical power source or other sophisticated instruments to move the particles. Evaporation provides a very simple way of concentrating particles and has potential in medical diagnosis. For example, researchers at Vanderbilt University were recently awarded a Gates Foundation Research Fund for proposing the use of the coffee-ring phenomenon for malaria detection in developing countries."

The researchers are currently optimizing the ring formation parameters and will then explore the application of this approach toward biosensing technologies that are being developed in Ho's laboratory.


'/>"/>

Contact: Matthew Chin
mchin@support.ucla.edu
310-206-0680
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... until they hatched 4.5 years later, according to a ... PLOS ONE by Bruce Robison from Monterey ... have a single reproductive period during their life, where ... eggs until they hatch. Shallow-water octopuses typically care for ... is known about the brooding of deep-sea species. Using ...
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... "Environmental Nanoparticles: Science, Ethics & Policy" on Nov. ... Center in Newark, Del. The registration deadline is ... co-sponsored by UD,s Center for Critical Zone Research ... will include presentations by nationally and internationally recognized ...
... the first critical steps in unraveling the mysteries of ... that afflicts 500,000 people worldwide each year and nearly ... An international team led by Murat Gunel, professor ... and chair of genetics, and a Howard Hughes Medical ...
... Conn. If climate disasters are to be averted, atmospheric carbon ... today, according to a study published in Open Atmospheric ... the United States, the United Kingdom and France. ... a planet similar to that on which civilization developed, an optimum ...
Cached Biology News:Workshop on environmental nanoparticles at UD, Nov. 10-11 2Yale researchers unravel mystery of brain aneurysms 2Revised theory suggests carbon dioxide levels already in danger zone 2
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... When ... has made a lasting impact on both agriculture and weed science around the globe. He ... techniques to benefit farmers. Thousands of students have followed in his footsteps and are now making ... ...
... results of this study will be presented during the ... June 3, 2009 COLUMBIA, Md., May 30 Lead ... from the University of Miami , evaluated whether ... determining rejection or infection in kidney transplant recipients. Patients ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5